E-LIB Suche - Ergebnisse für: Gül Mutlu, Yaşa

1

Germline CEBPA Mutation as a Rare Cause of Chronic Neutrope..:

Askin, Abdullah Emre ; Bektas, Sebnem ; Serin, Istemi...
Indian Journal of Hematology and Blood Transfusion. 40 (2024) 3 - p. 527-530 , 2024

Link: https://doi.org/10.1007/..

2

Single agent vemurafenib or rituximab-vemurafenib combinati..:

Yiğit Kaya, Süreyya ; Mutlu, Yaşa Gül ; Malkan, Ümit Yavuz...
Leukemia Research. 140 (2024) - p. 107495 , 2024

Link: https://doi.org/10.1016/..

3

Pegaspargase, venetoclax, and nelarabine: a successful brid..:

Yiğit Kaya, Süreyya ; Bektas, Sebnem ; Askin, Abdullah Emre...
Annals of Hematology. 102 (2023) 6 - p. 1599-1600 , 2023

Link: https://doi.org/10.1007/..

4

Intravascular B‐cell lymphoma with generalized telangiectas..:

Erol, Vedat Bugra ; Mutlu, Yaşa Gul ; Balik, Berrin...
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 21 (2023) 9 - p. 1025-1027 , 2023

Link: https://doi.org/10.1111/..

5

Intravaskuläres B‐Zell‐Lymphom mit generalisierten Teleangi..:

Erol, Vedat Bugra ; Mutlu, Yaşa Gul ; Balik, Berrin...
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 21 (2023) 9 - p. 1025-1028 , 2023

Link: https://doi.org/10.1111/..

6

Plerixafor in autologous stem cell transplantation: Does it..:

Serin, Istemi ; Sevindik, Omur Gokmen ; Balik Aydin, Berrin...
Transfusion and Apheresis Science. 62 (2023) 6 - p. 103809 , 2023

Link: https://doi.org/10.1016/..

7

Relapsed refractory multiple myeloma with CNS involvement s..:

Mutlu, Yasa Gul ; Yıgıt Kaya, Sureyya ; Maral, Senem...
Frontiers in Immunology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

8

The role of obesity on autologous bone marrow transplant an..:

Sadri, Sevil ; İdrisoğlu, Cem ; Mutlu, Yasa Gul...
Journal of Surgery and Medicine. 7 (2023) 9 - p. 531-535 , 2023

Link: https://doi.org/10.28982..

9

Prognostic Factors and Intensive Care Outcome in Post-Trans..:

Mutlu, Yaşa Gül ; Aydin, Berrin Balik ; Erdogan, Cem...
Indian Journal of Hematology and Blood Transfusion. 39 (2022) 2 - p. 167-172 , 2022

Link: https://doi.org/10.1007/..

10

To rechallenge or not to rechallenge, that is the question?..:

Sevindik, Omur Gokmen ; Mergen, Mahmut ; Mergen, Sena...
Annals of Hematology. 101 (2022) 11 - p. 2545-2547 , 2022

Link: https://doi.org/10.1007/..

11

Clinical Characteristics and Outcomes of COVID-19 in Turkis..:

Civriz Bozdağ, Sinem ; Seval, Güldane Cengiz ; Yönal Hindilerden, İpek...
Turkish Journal of Hematology. 39 (2022) 1 - p. 43-54 , 2022

Link: https://doi.org/10.4274/..

12

First-line Usage of Daratumumab, Lenalidomide, Dexamethason..:

Sevindik, Omur Gokmen ; Mutlu, Yasa Gul ; Aydin, Berrin Balik.
HemaSphere. 6 (2022) 7 - p. e728 , 2022

Link: https://doi.org/10.1097/..

13

Persistent Polyclonal B-cell Lymphocytosis with Binucleated..:

Balık Aydın, Berrin ; Mutlu, Yaşa Gül ; Sevindik, Ömür Gökmen
Turkish Journal of Hematology. , 2021

Link: https://doi.org/10.4274/..

14

Blinatumomab therapy in a relapsed acute lymphoblastic leuk..:

Açar, İbrahim Halil ; Mutlu, Yasa Gul ; Dincyurek, Huseyin Derya.
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 18 , 2020

Link: https://doi.org/10.1016/..

15

IBCL-386: Rituximab-Vemurafenib Combination for the Treatme..:

Sevindik, Ömür ; Gemici, Aliihsan ; Mutlu, Yasa Gul..
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) - p. S286 , 2020

Link: https://doi.org/10.1016/..